Journal
CLINICAL INFECTIOUS DISEASES
Volume 46, Issue 4, Pages 567-570Publisher
UNIV CHICAGO PRESS
DOI: 10.1086/526775
Keywords
-
Categories
Funding
- NIAID NIH HHS [T32 AI055435, K23-AI-060887-01] Funding Source: Medline
Ask authors/readers for more resources
Eighteen patients received tigecycline as treatment for infection due to multidrug-resistant gram-negative bacilli, including Acinetobacter baumannii and Klebsiella pneumoniae carbapenemase - and extended-spectrum beta-lactamase-producing Enterobacteriaceae. Pretherapy minimum inhibitory concentration values for tigecycline predicted clinical success. Observed evolution of resistance during therapy raises concern about routine use of tigecycline in treatment of such infections when other therapies are available.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available